Electromed initiated with a Buy at Roth Capital

Roth Capital initiated coverage of Electromed (ELMD) with a Buy rating and $29 price target The company, which is focused on developing, manufacturing, and marketing noninvasive airway clearance therapy devices, is taking share by “offering a better technology with a pure-play focus and expanding the market with new clinical evidence and physician education,” the analyst tells investors. The firm believes the company can continue to post double-digit revenue growth with “meaningful operating leverage,” the analyst added.